Breaking News

Lonza, Eclipse in Bio-development Pact

Lonza will produce Phase I material at Slough site

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lonza and Eclipse have entered an agreement for the production of Eclipse’s novel cancer therapeutic antibody, ET-101, using Light Path Development Services. ET-101 is a novel therapeutic antibody designed to target cancer stem cells. Lonza will produce Phase I material at its development and manufacturing facility in Slough, UK. Dr. Christopher Reyes, chief scientific officer of Eclipse Therapeutics, said, “Lonza’s best-in-class antibody manufacturing capabilities will greatly support our deve...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters